Do Traders Think Rocket Pharmaceuticals Inc (RCKT) Can Keep Climbing Friday?

Rocket Pharmaceuticals Inc (RCKT) stock has risen 4.07% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Rocket Pharmaceuticals Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on RCKT!

See Full RCKT Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With RCKT Stock Today?

Rocket Pharmaceuticals Inc (RCKT) stock is higher by 1.41% while the S&P 500 is down -0.01% as of 11:54 AM on Friday, Nov 24. RCKT has gained $0.31 from the previous closing price of $21.91 on volume of 103,645 shares. Over the past year the S&P 500 has risen 13.13% while RCKT has gained 22.16%. RCKT lost -$3.17 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Rocket Pharmaceuticals Inc click here.

More About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. Click Here to get the full Stock Report for Rocket Pharmaceuticals Inc stock.